GURUFOCUS.COM » STOCK LIST » Energy » Oil & Gas » Core Laboratories Inc (NYSE:CLB) » Definitions » Sloan Ratio %

Core Laboratories (Core Laboratories) Sloan Ratio %

: 2.28% (As of Mar. 2023)
View and export this data going back to 1995. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Core Laboratories's Sloan Ratio for the quarter that ended in Mar. 2023 was 2.28%.

As of Mar. 2023, Core Laboratories has a Sloan Ratio of 2.28%, indicating the company is in the safe zone and there is no funny business with accruals.


Core Laboratories Sloan Ratio % Historical Data

The historical data trend for Core Laboratories's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core Laboratories Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.91 2.34 -28.73 -1.14 -0.28

Core Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -1.22 0.89 -0.28 2.28

Competitive Comparison

For the Oil & Gas Equipment & Services subindustry, Core Laboratories's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core Laboratories Sloan Ratio % Distribution

For the Oil & Gas industry and Energy sector, Core Laboratories's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Core Laboratories's Sloan Ratio % falls into.



Core Laboratories Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Core Laboratories's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(19.453-24.956
--3.856)/578.354
=-0.28%

Core Laboratories's Sloan Ratio for the quarter that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2023 )
=(23.714-16.497
--6.322)/593.617
=2.28%

Core Laboratories's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was 7.066 (Jun. 2022 ) + 7.524 (Sep. 2022 ) + 6.751 (Dec. 2022 ) + 2.373 (Mar. 2023 ) = $23.7 Mil.
Core Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 was 0.605 (Jun. 2022 ) + 5.85 (Sep. 2022 ) + 13.211 (Dec. 2022 ) + -3.169 (Mar. 2023 ) = $16.5 Mil.
Core Laboratories's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 was -2.785 (Jun. 2022 ) + -2.557 (Sep. 2022 ) + 1.058 (Dec. 2022 ) + -2.038 (Mar. 2023 ) = $-6.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Core Laboratories  (NYSE:CLB) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2023, Core Laboratories has a Sloan Ratio of 2.28%, indicating the company is in the safe zone and there is no funny business with accruals.


Core Laboratories Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Core Laboratories's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Core Laboratories (Core Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
6316 Windfern Road, Houston, TX, USA, 77040
Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Executives
Katherine Murray director 6316 WINDFERN ROAD, HOUSTON TX 77040
Mark Damian Tattoli officer: SVP, Gen Counsel & Secretary C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040
Kwaku Temeng director C/O CORE LABORATORIES LP, 2216 SHERIDAN STREET, HOUSTON TX 77002
Gwendolyn Schreffler officer: SVP C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040
Harvey Robert Klingensmith director P.O. BOX 131144, HOUSTON TX 77219-1114
Van Dijken Eeuwijk Monique director P.O. BOX 129, BILTHOVEN P7 3720 AC
Jan Willem Sodderland director DUINDISTEL 89, NOORDWIJK P7 2202 DE
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lawrence Bruno officer: President 6316 WINDFERN ROAD, HOUSTON TX 77040
Mark F Elvig officer: VP, Counsel & Secretary 6316 WINDFERN, HOUSTON TX 77040
Gregory Barry Barnett director 853 MILWAUKEE STREET, DENVER CO 80206
Kevin Daniels officer: CAO & Treasurer 6316 WINDFERN ROAD, HOUSTON TX 77040
Michael Straughen director 68 RUBISLAW DEN NORTH, ABERDEEN X0 AB15 4AN
Martha Z. Carnes director 6316 WINDFERN ROAD, HOUSTON TX 77040